经导管主动脉瓣置换的介入瓣膜的现状及展望

经导管主动脉瓣置换术（TAVR）经过最近几年快速发展已经取得巨大进步。迄今为止全球接受TAVR的患者数已近3万例,已成为无法耐受传统手术患者的标准备选治疗措施。从目前已临床应用的介入瓣膜到正在实验研究的新型介入瓣膜可以看出,未来介入瓣膜的发展目标是尺寸更小、长期有效、安全性高、并发症少、操作简单及定位精准。随着TAVR的推广,新型介入瓣的研发,操作者经验的积累,以及长期随访的开展,将给TAVR提供更科学的病例选择标准,减少介入手术的相关并发症,提高更安全有效的治疗效果。未来此项技术还会逐渐扩大适用人群的范围,成为代替传统的主动脉瓣置换术举足轻重的治疗措施。

Present and future use of transcatheter valve for transcatheter aortic valve replacement therapies

Tremendous progress has been made in transcatheter aortic valve replacement(TAVR) therapies in recent years and TAVR has become an alternative treatment to surgical aortic valve replacement(AVR),with nearly 30 000 procedures performed to date worldwide.Clinical application and investigation of transcatheter valves signify that the future transcatheter valve system will be targeted towards low-profile sheath,long-term efficacy,and safe and precise placement.With wider application and development of transcatheter valves,cumulative experiences and long-term follow-up of TAVR therapies,better criteria will be established for patient selection.Complications will be reduced and safer and more effective treatment results will be achieved.TAVR therapies will be applied to a larger subset of patients and become an important alternative to future conventional aortic valve replacement.